DK2675476T3 - Fremgangsmåde til fremstilling af PRRSV i kommerciel skala - Google Patents

Fremgangsmåde til fremstilling af PRRSV i kommerciel skala Download PDF

Info

Publication number
DK2675476T3
DK2675476T3 DK12706508.4T DK12706508T DK2675476T3 DK 2675476 T3 DK2675476 T3 DK 2675476T3 DK 12706508 T DK12706508 T DK 12706508T DK 2675476 T3 DK2675476 T3 DK 2675476T3
Authority
DK
Denmark
Prior art keywords
virus
harvest
prrsv
bioreactor
medium
Prior art date
Application number
DK12706508.4T
Other languages
English (en)
Inventor
Elizabeth Jane Berry
Fuad Tawfiq Haddadin
Ali Khazraeinazmpour
Jeremy Kroll
Sonia Regina Cantisano Malburg
Basurto Edgar Arnulfo Sandoval
Stephen Scheerer
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Application granted granted Critical
Publication of DK2675476T3 publication Critical patent/DK2675476T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)

Claims (16)

1. Fremgangsmåde til fremstilling af porcin reproduktions- og respirationssygdomsvirus (PRRSV) i kommerciel skala, hvilken fremgangsmåde omfatter: a) samtidigt at pode et storskalakulturmedium med en pattedyrcellelinje, som tillader PRRSV-infektion, i en bioreaktor og inficere pattedyrcellerne med en PRRSV; b) at opformere virus i 5 til 7 dage efter infektion; c) at gennemføre et første indhøstningstrin ved at fjerne mediet fra bioreaktoren og isolere opformeret virus derfra; d) at genopfylde mediet i bioreaktoren og opformere virus i 1 til 4 dage; e) at gennemføre et andet indhøstningstrin ved at fjerne mediet fra bioreaktoren og isolere opformeret virus derfra; f) at genopfylde mediet i bioreaktoren og opformere virus i 1 til 4 dage, og g) at gennemføre et tredje indhøstningstrin ved at fjerne mediet fra bioreaktoren og isolere opformeret virus derfra.
2. Fremgangsmåde ifølge krav 1, hvilken fremgangsmåde yderligere omfatter mindst et gentilførsels- og indhøstningstrin efter det tredje indhøstningstrin, omfattende at genopfylde medium i bioreaktoren og at opformere virus i 1 til 4 dage og at gennemføre et fjerde indhøstningstrin ved at fjerne mediet fra bioreaktoren og isolere opformeret virus derfra.
3. Fremgangsmåde ifølge krav 1, hvor den tilsigtede infektionsfaktor (MOI) er 0,01 til 0,30.
4. Fremgangsmåde ifølge krav 1, hvor pattedyrcellerne indplantes med en tæthed på cirka 7 x 108 til 1,0 x 109 per 300 I bioreaktor.
5. Fremgangsmåde ifølge krav 4, hvor celleindplantningstætheden er cirka 1,00 x 109 per 300 I bioreaktor.
6. Fremgangsmåde ifølge krav 5, hvor infektionen sker med cirka 7 x 108 viruspartikler per 300 I bioreaktor.
7. Fremgangsmåde ifølge krav 1, omfattende at overvåge dextrosekoncentrationen i mediet, hvor det første indhøstningstrin gennemføres på den første dag, når dextrosekoncentrationen i mediet falder til under 0,1 g/l.
8. Fremgangsmåde ifølge krav 1, hvor den anden indhøstning gennemføres 1 eller 2 dage efter mediegentilførsel.
9. Fremgangsmåde ifølge krav 1, hvor den tredje indhøstning gennemføres 1 til 4 dage efter anden mediegentilførsel.
10. Fremgangsmåde ifølge krav 1, hvor kulturmediet tilsættes til bioreaktoren dagen inden eller same dag forud for indbringning af pattedyrcellelinjen og nævnte PRRS.
11. Fremgangsmåde ifølge krav 1, hvor kulturmediet tilsættes til bioreaktoren én dag inden indbringning af pattedyrcellelinjen og nævnte PRRS.
12. Fremgangsmåde ifølge krav 1, hvor bioreaktorens temperatur indstilles til mellem 34 °C og 38 °C.
13. Fremgangsmåde ifølge krav 1, hvor mediet omfatter 5 % v/v bestrålet kalvefo-sterserum.
14. Fremgangsmåde ifølge krav 1, hvor nævnte PRRSV er udvalgt fra gruppen bestående af PRRSV-stamme ECACC 11012501, ECACC 11012502, VR 2332, Lelystad-virusstamme (Lelystad Agent (CDI-NL-2.91), eller andre stammer såsom hine deponeret under tilgangsnumrene ECACC 04102703, ECACC 04102702, ECACC 04102704, CNCM-tilgangsnr. 1-1140, CNCM-tilgangsnr. 1-1387, CNCM-tilgangsnr. 1-1388, ATCC VR 2332, VR 2385, VR 2386, VR 2429, VR 2474 og VR 2402; CNCM 1-1102, CNCM 1-1140, CNCM I-1387, CNCM 1-1388 eller ECACC V93070108; ATCC-deponering VR-2332, ATCC-deponering VR-2368; ATCC VR-2495; ATCC VR 2385, ATCC VR 2386, ATCC VR 2429, ATCC VR 2474 og ATCC VR 2402.
15. Fremgangsmåde til fremstilling af en PRRSV i kommerciel skala, hvilken fremgangsmåde omfatter: a. samtidig at pode både pattedyrceller, som tillader infektion med nævnte PRRSV, og nævnte PRRSV i en bioreaktor indeholdende et medium, der egner sig til dyrkning af cellerne; og b. at gennemføre tre på hinanden følgende indhøstningstrin, hvor PRRSV indhøstes, idet mediet genopfyldes efter hver af den første og den anden indhøstning, og hvor: i. den første indhøstning gennemføres på den første dag, hvor mediets dextrosekoncentration falder til under 0,1 g/l; ii. den anden indhøstning gennemføres 1 eller 2 dage efter tilsætning af mediet efter den første indhøstning; og iii. den tredje indhøstning gennemføres mellem 1 og 4 dage efter tilsætning af mediet efter den anden indhøstning.
16. Fremgangsmåde til fremstilling i kommerciel skala af porcin reproduktions- og respirationssygdomsvirus (PRRSV), hvilken fremgangsmåde omfatter: a) samtidigt at pode et storskalakulturmedium med en pattedyrcellelinje, som tillader PRRSV-infektion, i en rulleflaske og at inficere pattedyrcellerne med en PRRSV; b) at opformere virus i 5 til 7 dage efter infektion; c) at gennemføre et første indhøstningstrin ved at fjerne mediet fra rulleflasken og isolere opformeret virus derfra; d) at genopfylde mediet i rulleflasken og opformere virus i cirka 2 dage; e) at gennemføre et andet indhøstningstrin ved at fjerne mediet fra rulleflasken og isolere opformeret virus derfra; f) at genopfylde mediet i rulleflasken og opformere virus i cirka 2 dage, og g) at gennemføre et tredje indhøstningstrin ved at fjerne mediet fra bioreaktoren og isolere opformeret virus derfra.
DK12706508.4T 2011-02-17 2012-02-14 Fremgangsmåde til fremstilling af PRRSV i kommerciel skala DK2675476T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161444071P 2011-02-17 2011-02-17
PCT/EP2012/052476 WO2012110490A1 (en) 2011-02-17 2012-02-14 Commercial scale process for production of prrsv

Publications (1)

Publication Number Publication Date
DK2675476T3 true DK2675476T3 (da) 2015-12-14

Family

ID=45774164

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12706508.4T DK2675476T3 (da) 2011-02-17 2012-02-14 Fremgangsmåde til fremstilling af PRRSV i kommerciel skala

Country Status (20)

Country Link
US (1) US9944902B2 (da)
EP (1) EP2675476B1 (da)
JP (1) JP2014506795A (da)
KR (1) KR101983980B1 (da)
CN (1) CN103370077B (da)
AR (1) AR085271A1 (da)
AU (1) AU2012217170B2 (da)
BR (1) BR112013020966B1 (da)
CA (1) CA2827337C (da)
CL (1) CL2013002169A1 (da)
CO (1) CO6791569A2 (da)
DK (1) DK2675476T3 (da)
EA (1) EA031432B1 (da)
ES (1) ES2553879T3 (da)
MX (1) MX346636B (da)
MY (1) MY183980A (da)
SG (1) SG192821A1 (da)
TW (1) TWI652346B (da)
UA (1) UA112860C2 (da)
WO (1) WO2012110490A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2675475T3 (da) 2011-02-17 2015-09-14 Boehringer Ingelheim Vetmed Ny europæisk prrsv-stamme
EP3083947B1 (en) 2013-12-20 2019-04-03 Boehringer Ingelheim Vetmedica GmbH Prrs virus variant, european prrs virus cdna clone, and uses thereof
CN105385661B (zh) * 2014-09-03 2019-02-05 普莱柯生物工程股份有限公司 一种猪圆环病毒2型大规模培养的方法及其应用
KR102320269B1 (ko) 2020-01-22 2021-11-03 대한민국 돼지생식기호흡기증후군 바이러스의 감염력 향상 또는 억제를 위한 돼지 대식세포 분화 및 극성화 방법
BR112023001324A2 (pt) 2020-07-24 2023-02-14 Boehringer Ingelheim Animal Health Usa Inc Combinação de vacina de suíno

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137631A (en) 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3959457A (en) 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
US4015100A (en) 1974-01-07 1977-03-29 Avco Everett Research Laboratory, Inc. Surface modification
US4122167A (en) 1977-02-09 1978-10-24 Merck & Co., Inc. Respiratory synctial vaccine
EP0000062A1 (en) 1977-06-07 1978-12-20 Joseph George Spitzer Vapor tap valve for aerosol containers used with inflammable propellants, and container provided therewith
US4205060A (en) 1978-12-20 1980-05-27 Pennwalt Corporation Microcapsules containing medicament-polymer salt having a water-insoluble polymer sheath, their production and their use
US4224412A (en) 1979-05-01 1980-09-23 Dorofeev Viktor M Living virus culture vaccine against canine distemper and method of preparing same
DD145705A1 (de) 1979-08-31 1981-01-07 Peter Solisch Herstellungsverfahren von organspezifischen retrovirusimmunpraeparaten fuer prophylaxe,therapie und diagnostik
US4554159A (en) 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4468346A (en) 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
DE3405100A1 (de) 1984-02-14 1985-08-14 Drägerwerk AG, 2400 Lübeck Pt-katalysator auf einem traeger als luftreinigungsmittel
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4606940A (en) 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
US5206163A (en) 1985-07-08 1993-04-27 Chiron Corporation DNA encoding bovine diarrhea virus protein
ZA864879B (en) 1985-07-08 1987-03-25 Wallone Region Vaccines and diagnostics derived from boving diarrhoea virus
US4753884A (en) 1986-01-28 1988-06-28 Novagene, Inc. Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
JPS62198626A (ja) 1986-02-26 1987-09-02 Biseibutsu Kagaku Kenkyusho:Kk 血球凝集性脳脊髄炎ウイルス感染症予防ワクチン
FR2602791B1 (fr) 1986-08-18 1988-11-10 Ministere Agri Direction Quali Procede de culture du virus de la rhinotracheite infectieuse de la dinde, et vaccin prepare a partir du virus ainsi obtenu
NZ222465A (en) 1986-11-07 1992-11-25 Pasteur Institut Nanb (non a, non b hepatitis viral) antigen
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
DE3833925A1 (de) 1988-03-11 1989-09-21 Inst Angewandte Biotechnologie Verfahren und herstellung von virus und viralem antigen und vorrichtung hierzu
US5213759A (en) 1988-05-05 1993-05-25 Elopak Systems A.G. Sterilization
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5132117A (en) 1990-01-11 1992-07-21 Temple University Aqueous core microcapsules and method for their preparation
AU7007491A (en) 1990-02-02 1991-08-08 Schweiz. Serum- & Impfinstitut Bern Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses
US5620691A (en) 1991-06-06 1997-04-15 Stichting Centraal Diergeneeskundig Instituut Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
US6080570A (en) 1991-08-26 2000-06-27 Boehringer Ingelheim Vetmedica, Inc. Method of producing a vaccine for Swine Infertility and Respiratory Syndrome
US5846805A (en) 1991-08-26 1998-12-08 Boehringer Ingelheim Animal Health, Inc. Culture of swine infertility and respiratory syndrome virus in simian cells
US6982160B2 (en) 1991-08-26 2006-01-03 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions that include SIRS virus
CA2076744C (en) 1991-08-26 2000-06-27 Danny W. Chladek Viral agent associated with mystery swine disease
CA2116348C (en) 1991-08-26 2001-07-03 James E. Collins Sirs vaccine and diagnosis method
US6042830A (en) * 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
AU2696792A (en) 1991-09-16 1993-04-27 David A Benfield Vaccine for mystery swine disease and method for diagnosis thereof
AU2684792A (en) 1991-10-14 1993-05-21 Akzo Nobel N.V. Porcine reproductive respiratory syndrome vaccine and diagnostic
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
TW289731B (da) 1992-07-09 1996-11-01 Akzo Nv
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US5419907A (en) 1992-11-10 1995-05-30 Iowa State University Research Foundation, Inc. Pathogenic porcine respiratory coronavirus
CZ289743B6 (cs) 1993-02-08 2002-03-13 Bayer Corporation Izolát viru vepřového reprodukčního a respiračního syndromu PRRSV, způsob kultivace PRRSV, tkáňová kultura, způsob přípravy vakcíny a vakcína obsahující PRRSV izolát
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
EP0659885A1 (en) 1993-12-21 1995-06-28 Akzo Nobel N.V. Vaccine against viruses associated with antibody-dependent-enhancement of viral infectivity
DE4407489A1 (de) 1994-03-07 1995-09-14 Bayer Ag Vakzine zur Prävention von Respirations- und Reproduktionserkrankungen des Schweines
HRP950097A2 (en) * 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
DK0676467T3 (da) 1994-04-11 2002-01-21 Akzo Nobel Nv Europæiske vaccinestammer af det porcine reproduktive respiratoriske syndromvirus (PRRSV)
AU2386595A (en) 1994-04-15 1995-11-10 Children's Hospital Of Philadelphia, The Aqueous solvent encapsulation method, apparatus and microcapsules
GB2289279B (en) 1994-05-13 1998-09-16 Iberica Cyanamid Diagnostic kits and vaccines containing recombinant PRRSV proteins
DK0783321T3 (da) 1994-08-05 2006-10-02 Univ Minnesota VR-2332 viral nucleotidsekvens og fremgangsmåder til anvendelse
ES2223058T3 (es) 1995-03-14 2005-02-16 Akzo Nobel N.V. Expresion en la misma celula de polipeptidos del virus del sindrome reproductivo y respiratorio porcino.
US5690940A (en) 1995-06-21 1997-11-25 Regents Of The University Of Minnesota Low pathogencity PRRS live virus vaccines and methods of preparation thereof
EP0841942B2 (fr) * 1995-08-01 2007-12-12 Sanofi Pasteur Procede de production industrielle d'un vaccin contre l'encephalite japonaise et vaccin obtenu
ES2102971B1 (es) 1996-01-25 1998-03-01 Hipra Lab Sa Nueva cepa atenuada del virus causante del sindrome respiratorio y reproductivo porcino (prrs), las vacunas y medios de diagnostico obtenibles con la misma y los procedimientos para su obtencion.
WO1997031651A1 (en) 1996-03-01 1997-09-04 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
US6015663A (en) 1996-03-01 2000-01-18 The United States Of America As Represented By The Secretary Of Agriculture Restriction enzyme screen for differentiating porcine reproductive and respiratory syndrome virus strains
US5866401A (en) 1996-03-01 1999-02-02 Schering Corporation Porcine reproductive and respiratory syndrome vaccine
US5976537A (en) 1996-07-02 1999-11-02 The United States Of America As Represented By The Secretary Of Agriculture Porcine reproductive and respiratory syndrome vaccine
ATE199022T1 (de) 1996-10-09 2001-02-15 Akzo Nobel Nv Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des sweins (prrsv)
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
US20040224327A1 (en) 1996-10-30 2004-11-11 Meulenberg Johanna Jacoba Maria Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
WO1998035023A1 (en) * 1997-02-07 1998-08-13 Origen, Inc. Method for growing porcine reproductive and respiratory syndrome virus for use as vaccines and diagnostic assays
BR9809221A (pt) 1997-05-06 2000-07-04 Stichting Dienst Landbouwkundi Peptìdeo gerador de anticorpos, composição imunogênica, vacina para profilaxia de infecções de prrs, uso da mesma, anticorpo sintético, kit de teste de diagnóstico,uso do mesmo, e, processo para testar a ocorrência de prrs em um porco ou em uma vara de porcos
US6140486A (en) 1997-06-04 2000-10-31 Calgene Llc Production of polyunsaturated fatty acids by expression of polyketide-like synthesis genes in plants
AU7960598A (en) 1997-06-05 1998-12-21 Origen, Inc. Recombinant porcine reproductive and respiratory syndrome virus (prrsv) for use as a vaccine
US7211379B2 (en) 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
CA2290220C (en) 1998-12-22 2013-11-19 Pfizer Products Inc. An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof
US7618797B2 (en) 1998-12-22 2009-11-17 Pfizer Inc Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7132106B2 (en) 1998-12-22 2006-11-07 Pfizer Inc. Infectious cDNA clone of North American porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
US7691389B2 (en) 1998-12-22 2010-04-06 Pfizer Inc Infectious cDNA clone of north american porcine reproductive and respiratory syndrome (PRRS) virus and uses thereof
FR2789695B1 (fr) 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
PL204373B1 (pl) 1999-03-08 2010-01-29 Boehringer Ingelheim Vetemendi Replikony zespołu reprodukcyjnego i oddechowego świń (PRRSV), zastosowanie replikonów PRRSV, szczepionki zawierające replikony PRRSV i zastosowanie tych szczepionek
JP4778620B2 (ja) 1999-04-22 2011-09-21 ユナイテッド ステイツ デパートメント オブ アグリカルチャー 分離株ｊａ−１４２に基づく、豚繁殖・呼吸障害症候群ワクチン
US20040213805A1 (en) 1999-10-12 2004-10-28 Verheije Monique Helene Deletions in arterivirus replicons
US20020012670A1 (en) 2000-01-26 2002-01-31 Knut Elbers Recombinant attenuation of porcine reproductive and respiratory syndrome (PRRSV)
ATE333500T1 (de) 2000-02-08 2006-08-15 Univ Minnesota Virus des porzinen reproduktiven und respiratorischen syndroms und dessen verwendung
EP1156111A1 (en) 2000-05-19 2001-11-21 Stichting Dienst Landbouwkundig Onderzoek Chimeric arterivirus-like particles
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
EP1397498A1 (en) 2001-05-21 2004-03-17 ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V. Delections in arterivirus replicons
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US6841364B2 (en) 2002-01-22 2005-01-11 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
ATE557082T1 (de) 2002-04-05 2012-05-15 Boehringer Ingelheim Vetmed Sequenz positionen zur anpassung bei prrsv
US7335361B2 (en) 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
US7722878B2 (en) 2004-06-17 2010-05-25 Boehringer Ingelheim Vetmedica, Inc. PRRSV subunit vaccines
WO2006009880A2 (en) 2004-06-18 2006-01-26 Regents Of The University Of Minnesota Identifying virally infected and vaccinated organisms
US20060063151A1 (en) 2004-09-21 2006-03-23 Michael Roof Porcine reproductive and respiratory syndrome isolates and methods of use
US7632636B2 (en) 2004-09-21 2009-12-15 Boehringer Ingelheim Vetmedica, Inc. Porcine reproductive and respiratory syndrome isolates and methods of use
AU2006205852A1 (en) 2005-01-13 2006-07-20 Boehringer Ingelheim Vetmedica Gmbh Improved PRRS vaccines
CN101495138B (zh) 2005-11-29 2014-01-08 衣阿华州立大学研究基金公司 猪繁殖与呼吸综合征病毒（prrsv）的保护性抗原决定子的鉴定及其用途
WO2008109237A2 (en) * 2007-02-13 2008-09-12 Washington State University Research Foundation Macrophage cell-lines for propagation of porcine reproductive and respiratory syndrome virus
WO2008121958A1 (en) 2007-04-02 2008-10-09 Boehringer Ingelheim Vetmedica, Inc. Use of prrsv vaccines to reduce pcv2 viremia
US20100003278A1 (en) 2008-07-03 2010-01-07 Boehringer Ingelheim Vetmedica, Inc. Immunological Compositions Effective for Lessening the Severity or Incidence of PRRSV Signs and Methods of Use Thereof
CA2734390A1 (en) 2008-08-25 2010-03-04 Boehringer Ingelheim Vetmedica, Inc. Vaccine against highly pathogenic porcine reproductive and respiratory syndrome (hp prrs)
US20100129398A1 (en) 2008-11-26 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Materials and Methods for Control of Porcine Reproductive and Respiratory Syndrome
EP2558118B1 (en) 2010-04-16 2019-06-05 Universiteit Gent Cross-protecting vaccine for porcine reproductive and respiratory syndrome virus
DK2675475T3 (da) 2011-02-17 2015-09-14 Boehringer Ingelheim Vetmed Ny europæisk prrsv-stamme
EP3083947B1 (en) 2013-12-20 2019-04-03 Boehringer Ingelheim Vetmedica GmbH Prrs virus variant, european prrs virus cdna clone, and uses thereof

Also Published As

Publication number Publication date
CO6791569A2 (es) 2013-11-14
AR085271A1 (es) 2013-09-18
BR112013020966B1 (pt) 2020-05-26
JP2014506795A (ja) 2014-03-20
KR20140006038A (ko) 2014-01-15
AU2012217170A1 (en) 2013-07-11
EA201300916A1 (ru) 2014-02-28
TWI652346B (zh) 2019-03-01
KR101983980B1 (ko) 2019-05-30
BR112013020966A2 (pt) 2016-10-11
EP2675476B1 (en) 2015-09-16
CN103370077A (zh) 2013-10-23
MX346636B (es) 2017-03-27
MX2013009479A (es) 2013-10-25
UA112860C2 (uk) 2016-11-10
CA2827337A1 (en) 2012-08-23
CN103370077B (zh) 2016-10-26
EA031432B1 (ru) 2019-01-31
ES2553879T3 (es) 2015-12-14
AU2012217170B2 (en) 2016-07-28
WO2012110490A1 (en) 2012-08-23
EP2675476A1 (en) 2013-12-25
US20120213741A1 (en) 2012-08-23
SG192821A1 (en) 2013-09-30
CA2827337C (en) 2019-07-09
CL2013002169A1 (es) 2014-05-16
US9944902B2 (en) 2018-04-17
MY183980A (en) 2021-03-17
TW201247872A (en) 2012-12-01

Similar Documents

Publication Publication Date Title
US10668144B2 (en) European PRRSV strain
US7368117B2 (en) PRRS vaccines
DK2675476T3 (da) Fremgangsmåde til fremstilling af PRRSV i kommerciel skala